An investigational dual glucagon and GLP-1 receptor agonist showing strong efficacy for metabolic-associated steatohepatitis and obesity in clinical trials.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →Survodutide — developed under the research designation BI 456906 in a collaboration between Boehringer Ingelheim and Zealand Pharma — is an investigational dual glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) agonist currently in Phase 2 and Phase 3 clinical development. Its primary clinical focus is metabolic dysfunction-associated steatohepatitis (MASH), the more severe inflammatory form of liver disease previously called non-alcoholic steatohepatitis (NASH), though it is also being evaluated for broader obesity and metabolic syndrome applications. As of early 2026, survodutide has generated considerable interest within hepatology and endocrinology research communities following Phase 2 trial results that showed meaningful reductions in liver fat and histological improvement in MASH patients — outcomes the field has been pursuing with only limited success for decades.
The compound is a peptide-based dual agonist, meaning it is engineered to activate two distinct receptor systems simultaneously with a single molecule. This dual mechanism is the defining feature that differentiates survodutide from pure GLP-1 receptor agonists like liraglutide and semaglutide. While GLP-1 receptor activation provides robust appetite suppression and incretin-based glycemic control, glucagon receptor activation adds a distinct metabolic dimension: it directly drives hepatic fat oxidation and stimulates thermogenesis in a way that GLP-1 receptor stimulation alone does not. The theoretical advantage of combining these two receptor targets is that the liver-directed fat-burning effect of glucagon signaling could complement the appetite-reducing effects of GLP-1 to produce superior liver and body composition outcomes compared to either mechanism in isolation.
Zealand Pharma contributed the peptide engineering expertise for the molecule, applying backbone modifications to create a compound with appropriate receptor binding kinetics and pharmacokinetic properties suitable for once-weekly subcutaneous dosing. The collaboration brings together Zealand’s peptide design capability and Boehringer Ingelheim’s clinical development infrastructure, a partnership that has been productive across multiple therapeutic asset programs for both companies.
It is important to note that survodutide has not yet received regulatory approval from the FDA, EMA, or any major regulatory body as of the date of publication. All clinical findings described in this article derive from Phase 2 data and ongoing Phase 3 trials; outcomes from registration-enabling trials are pending. This content is for research and educational use only. For additional compound comparisons, visit our Peptide Database or ask the AI Coach for mechanism-focused breakdowns.
The GLP-1 receptor component of survodutide’s dual mechanism works through the same foundational pathway established across the GLP-1 receptor agonist class. GLP-1R engagement activates Gs-coupled adenylyl cyclase signaling in pancreatic beta cells, driving glucose-dependent insulin secretion and glucagon suppression in alpha cells. This incretin-mediated glycemic action is complemented by central nervous system effects: GLP-1R stimulation in the hypothalamic arcuate nucleus activates POMC neurons while suppressing NPY/AgRP activity, effectively resetting hypothalamic energy balance signaling toward reduced caloric intake. In the brainstem’s nucleus tractus solitarius, GLP-1R activation amplifies peripheral satiety signals arriving via vagal afferent pathways. Together, these central and peripheral mechanisms produce the appetite suppression that drives the body weight reduction observed with GLP-1 receptor agonists broadly. In survodutide, this GLP-1 component serves as the foundational metabolic scaffold — maintaining glycemic safety and weight reduction — upon which the glucagon receptor’s hepatic effects are layered. The precise ratio of GLP-1R to GCGR agonist activity in survodutide is a proprietary aspect of the compound’s design, engineered to balance hepatic fat oxidation against the glucagon-mediated glycemic raising that would occur if GCGR activity were unmodulated. The concurrent GLP-1R insulin secretory action effectively counterbalances any hyperglycemic tendency from glucagon receptor stimulation.
The defining mechanistic distinction of survodutide relative to pure GLP-1 agonists is its activation of the glucagon receptor (GCGR), which is expressed at high levels in the liver. Endogenous glucagon functions as a counter-regulatory hormone released during fasting or hypoglycemia; at the hepatic level, it drives glycogenolysis, gluconeogenesis, and — critically — the oxidation of fatty acids as fuel. GCGR activation triggers cAMP elevation in hepatocytes, which activates protein kinase A and downstream phosphorylation events that ultimately activate AMP-activated protein kinase (AMPK). AMPK is the cell’s master fuel sensor: when AMP:ATP ratios are elevated or when AMPK is pharmacologically activated, it phosphorylates and inhibits acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels. Since malonyl-CoA is an allosteric inhibitor of CPT-1α — the enzyme that shuttles long-chain acyl-CoA esters across the inner mitochondrial membrane for beta-oxidation — its reduction effectively removes the brake on hepatic fatty acid oxidation. This AMPK/ACC/CPT-1α axis is the molecular pathway through which survodutide’s glucagon component drives the liver to consume its own accumulated fat stores. In the setting of MASH, where hepatocytes are engorged with triglycerides and lipid intermediates driving oxidative stress and inflammation, this enhanced mitochondrial fat oxidation addresses the substrate overload that underlies the disease pathophysiology. Additionally, glucagon receptor activation stimulates hepatic thermogenesis through fibroblast growth factor 21 (FGF21) induction, providing an additional energy expenditure pathway beyond the gut-mediated mechanisms of GLP-1 agonism.
The therapeutic value of survodutide’s dual agonism is rooted in the synergy between its two receptor targets operating through partially non-overlapping cellular pathways. In the context of MASH, where disease burden arises from the intersection of excess hepatic lipid accumulation, mitochondrial dysfunction, oxidative stress, and inflammatory immune cell infiltration, addressing any single pathway in isolation has historically been insufficient to achieve robust histological improvement. The GLP-1R component contributes systemic caloric restriction (reducing hepatic lipid influx from diet and adipose lipolysis), improved insulin sensitivity (reducing lipogenesis driven by hyperinsulinemia), and anti-inflammatory signaling through GLP-1R on Kupffer cells and hepatic stellate cells. The GCGR component adds direct intrahepatocellular lipid clearance via enhanced beta-oxidation and FGF21-mediated thermogenesis. Together, these mechanisms simultaneously reduce hepatic lipid substrate supply and increase hepatic lipid substrate disposal — a dual assault on the lipid overload that drives MASH. Preclinical data in diet-induced obese rodent models have consistently shown that dual GLP-1R/GCGR agonists outperform either GLP-1 or glucagon monotherapy for hepatic steatosis and inflammation reduction, providing biological plausibility for the Phase 2 clinical observations with survodutide. The compound’s engineered balance between receptor targets is designed to maximize this synergy while avoiding the hyperglycemia, catabolism, and cardiovascular stress that would accompany unmodulated glucagon receptor agonism.
The Phase 2 randomized controlled trial evaluating survodutide in patients with MASH and liver fibrosis stage F1–F3 represents the compound’s most clinically significant dataset to date. The trial enrolled patients with biopsy-confirmed MASH defined by a NAFLD Activity Score of 4 or higher and randomized them to one of several survodutide dose levels or placebo with a 48-week treatment period. The primary endpoint — relative reduction in liver fat content measured by MRI-PDFF — was met with statistical significance across multiple dose cohorts. At the highest doses, the proportion of patients achieving a 30% or greater relative reduction in liver fat content was substantially higher than in the placebo group, and mean relative reductions exceeded 60% from baseline in the most responsive cohorts. These liver fat reductions are among the most robust reported in Phase 2 MASH trials. Secondary histological endpoints from paired biopsies provided an additional layer of clinical relevance: survodutide-treated patients showed higher rates of MASH resolution (defined as absence of steatohepatitis on follow-up biopsy) and non-worsening of fibrosis compared to placebo. The rates of at least one-stage improvement in fibrosis were numerically favorable for survodutide, though the trial was not powered to demonstrate fibrosis regression as a primary endpoint — this will be the defining challenge for the ongoing Phase 3 program, as fibrosis improvement represents the regulatory gold standard for MASH drug approval.
Beyond liver-specific endpoints, the Phase 2 MASH trial data for survodutide showed meaningful systemic metabolic improvements that position the compound competitively within the broader obesity and metabolic syndrome treatment landscape. Body weight reduction was dose-dependent and substantial: at the highest evaluated doses, mean percentage weight loss approached the range observed with once-weekly semaglutide in obesity trials, suggesting that the glucagon receptor component does not detract from — and may actually enhance — the weight reduction achievable through GLP-1R agonism alone. This weight reduction is clinically important in MASH because body weight loss of 10% or greater has been consistently associated with histological improvement in multiple pharmacological and lifestyle intervention studies. Metabolic biomarker improvements were consistent with this systemic effect: ALT and AST reductions tracked with liver fat changes, fasting insulin levels declined, and HOMA-IR — an index of insulin resistance — improved in a dose-dependent pattern. Triglyceride reductions were notable, likely reflecting both the reduction in hepatic very-low-density lipoprotein (VLDL) secretion that accompanies lower hepatic fat content and the AMPK-mediated suppression of lipogenic pathways. HDL cholesterol and blood pressure changes were modest and heterogeneous across dose cohorts, consistent with the Phase 2 nature of the data. A dedicated obesity-focused Phase 2 trial has also been conducted to characterize survodutide’s weight loss profile in patients without MASH, further broadening the compound’s potential development path.
The MASH therapeutic landscape has been characterized by a high historical rate of Phase 3 failure for agents that showed promise in Phase 2, making cross-trial comparisons inherently speculative. Nevertheless, survodutide’s Phase 2 liver fat reduction and histological signal places it within the upper tier of agents that have progressed into Phase 3 MASH development. Resmetirom (Rezdiffra), the first FDA-approved drug specifically for MASH with liver fibrosis, demonstrated its Phase 3 efficacy through thyroid hormone receptor-beta (THR-β) agonism — a mechanistically distinct approach. FGF21 analogues like pegbelfermin and efruxifermin have shown hepatic fat reduction and fibrosis signals in Phase 2. GLP-1 receptor agonists including semaglutide have shown MASH resolution in histological analyses but have not yet demonstrated statistically significant fibrosis improvement as a primary endpoint. Survodutide’s dual GLP-1R/GCGR mechanism theoretically addresses fibrosis through combined reduction in lipotoxic substrate load, improved insulin sensitivity (reducing TGF-β-driven stellate cell activation), and potential direct anti-inflammatory effects — but whether this translates to superior fibrosis regression in Phase 3 remains the central unanswered question. The ongoing Phase 3 trials will provide definitive comparative context.
The Phase 2 safety data for survodutide showed a tolerability profile broadly consistent with the GLP-1 receptor agonist class, with gastrointestinal adverse events — nausea, vomiting, diarrhea, and decreased appetite — representing the most commonly reported treatment-related events. These were predominantly mild to moderate in severity and occurred most frequently during dose escalation, consistent with GLP-1 class pharmacology. The glucagon receptor component of survodutide does not appear to significantly worsen gastrointestinal tolerability compared to GLP-1 monotherapy at the doses studied. A potential concern specific to GCGR agonism is an effect on glycemic regulation: excessive glucagon receptor stimulation could theoretically raise blood glucose, but the concurrent GLP-1R-mediated insulin secretion appears to counter this effect, and no significant hyperglycemia was observed in Phase 2 participants, including those with type 2 diabetes. No unexpected serious adverse events were reported that would suggest a novel safety liability relative to the GLP-1 class. Phase 3 trial safety data will be critical for characterizing the risk profile at the doses that will be advanced for registration, particularly for any hepatic safety signals relevant to patients with pre-existing liver disease.
Boehringer Ingelheim has initiated the SYNCHRONY Phase 3 program for survodutide in MASH, representing the pivotal trials that will determine whether the compound achieves regulatory approval. The primary efficacy endpoints in these registration trials focus on histological outcomes — specifically, the dual endpoint of MASH resolution without worsening of fibrosis and at least one stage improvement in fibrosis score — which represent the FDA and EMA benchmark for MASH drug approval established in guidance documents developed over the past decade. The trials are designed with sufficient power to detect histological improvement rates that would be clinically meaningful relative to placebo, and they incorporate biomarker-enriched patient selection strategies to identify the population most likely to respond. The SYNCHRONY program also includes a dedicated cardiovascular outcomes and safety assessment component, reflecting the regulatory requirement for comprehensive risk-benefit characterization in a metabolically complex patient population. Completion of the SYNCHRONY program and regulatory review will determine whether survodutide becomes the first dual GLP-1R/GCGR agonist to receive approval for MASH or any other metabolic indication.
Survodutide has not received regulatory approval, and therefore no approved dosing regimen exists. All dosing information presented here reflects Phase 2 trial protocols and published research data for educational purposes. In Phase 2 studies, survodutide was evaluated at doses ranging from approximately 1.2 mg to 6.0 mg administered subcutaneously once weekly. The Phase 2 MASH trial used a dose escalation design consistent with GLP-1 class best practices: patients began at a low starting dose and escalated through pre-specified increments over several weeks to reach their target maintenance dose. This titration approach was adopted to manage the gastrointestinal side effects that accompany GLP-1 receptor agonism, particularly during treatment initiation. The higher dose ranges that showed the most robust liver fat reduction and weight loss effects were associated with greater gastrointestinal adverse event frequency, a dose-response relationship that is typical of this peptide class. For reference on GLP-1 class dosing frameworks, visit our peptide calculators — noting that survodutide-specific calculators will be available once regulatory guidance establishes approved dosing parameters.
Like most long-acting GLP-1 receptor agonists, survodutide is administered via subcutaneous injection. The once-weekly dosing interval is achieved through structural modifications that extend the compound’s plasma half-life, enabling a consistent therapeutic exposure profile between weekly injections. The formulation details of the clinical trial drug product — including device type, injection volume, and excipient composition — are not fully disclosed in public domain publications, as they represent proprietary pharmaceutical development information. Approved injection sites in trials followed standard peptide injection protocols: abdomen, upper arm, and thigh with systematic site rotation. Once weekly subcutaneous administration is well-established as a patient-preferred delivery paradigm based on adherence and satisfaction data from semaglutide programs, and survodutide’s Phase 3 program is built on this foundation.
Phase 2 trial protocols for survodutide included patients with both obesity alone and obesity with comorbid type 2 diabetes, as well as patients with biopsy-confirmed MASH across fibrosis stages F1 through F3 (stopping short of F4 cirrhosis, where the risk-benefit and regulatory pathway differ). Patients with prior bariatric surgery, active alcohol use disorder, use of competing hepatically active medications, and decompensated liver disease were generally excluded from MASH-focused trials — standard exclusion criteria for the field. The inclusion of patients with type 2 diabetes in Phase 2 required careful glycemic monitoring given survodutide’s mixed receptor profile; the GLP-1 component provides anti-hyperglycemic action while the glucagon component carries theoretical glycemia-raising potential, and safety monitoring confirmed that the net glycemic effect was controlled in diabetic participants.
Based on Phase 2 dose-response data and the precedent established by approved once-weekly GLP-1 receptor agonists, it is reasonable to anticipate that the approved survodutide regimen — if Phase 3 trials are successful — will involve a standardized once-weekly subcutaneous dose following a multi-step escalation protocol beginning at a low starting dose. The specific approved maintenance dose will be determined by the dose that maximizes the efficacy-tolerability balance in the Phase 3 population, likely within the range evaluated in Phase 2. The AI Coach can provide updated information as Phase 3 data and regulatory review timelines become available, and the Peptide Database will be updated to reflect any approved labeling once regulatory decisions are issued.
Consistent with the GLP-1 receptor agonist class, the most common adverse events reported in survodutide Phase 2 trials were gastrointestinal in nature. Nausea was the most frequently reported event, followed by vomiting, diarrhea, decreased appetite, and constipation. These events were predominantly mild to moderate in severity and were most prevalent during the dose escalation phase of treatment, with many patients experiencing symptom improvement as they remained at a stable dose. The structured escalation protocol used in Phase 2 trials was designed to minimize gastrointestinal burden, and the rates of discontinuation due to gastrointestinal adverse events were consistent with what is observed across the GLP-1 class at comparable dose escalation rates. The contribution of the glucagon receptor component to gastrointestinal tolerability is an active area of evaluation; early data do not suggest that dual GLP-1R/GCGR agonism meaningfully worsens gastrointestinal tolerability relative to GLP-1 monotherapy, though this comparison requires larger head-to-head studies to confirm.
The dual receptor mechanism of survodutide raises theoretical concerns around glycemic regulation that warrant specific attention. Glucagon receptor agonism in isolation would be expected to raise blood glucose through hepatic glycogenolysis and gluconeogenesis stimulation. In the dual agonist context, the GLP-1R-mediated insulin secretory activity is designed to counterbalance this effect, and Phase 2 data confirmed that the compound did not produce clinically significant hyperglycemia in either non-diabetic or diabetic participants at evaluated doses. Conversely, the GLP-1 component’s glucose-dependent insulin secretory mechanism protects against hypoglycemia in the manner characteristic of the class. Cardiac effects — specifically the modest heart rate elevation associated with GLP-1 receptor agonism — have been observed with survodutide and require monitoring in patients with underlying arrhythmia or structural heart disease. Gallbladder events, including cholelithiasis and cholecystitis, are a class-level concern for GLP-1 agents and have been reported in Phase 2 survodutide trials; their frequency in Phase 3 populations and at approved doses will be important for full risk characterization.
An important and disease-specific safety consideration for survodutide development is the hepatic safety profile in patients with MASH and pre-existing fibrosis. Patients with MASH may have reduced hepatic metabolic reserve and potentially altered drug metabolism depending on fibrosis stage, warranting careful liver enzyme monitoring during trials. Phase 2 data showed that survodutide treatment was associated with reductions in ALT and AST — the opposite of hepatotoxicity — consistent with histological improvement rather than liver injury. No signals of drug-induced liver injury (DILI) were identified in Phase 2, and no patients with F4 (cirrhotic) disease were enrolled, leaving the safety profile in advanced cirrhosis to be characterized separately. Long-term hepatic safety will require Phase 3 data and post-marketing surveillance. The overall Phase 2 safety profile was considered sufficiently favorable by Boehringer Ingelheim and Zealand Pharma to advance to Phase 3, a decision that reflects confidence in the therapeutic index of the molecule at doses selected for registration trials.
Semaglutide is a selective GLP-1 receptor agonist — it activates only the GLP-1R. Survodutide is a dual agonist that activates both the GLP-1 receptor and the glucagon receptor simultaneously. The addition of glucagon receptor agonism adds direct hepatic fat oxidation through the AMPK/CPT-1α pathway, which semaglutide does not provide. This makes survodutide specifically suited to MASH treatment where hepatic lipid clearance is a primary therapeutic goal, whereas semaglutide’s primary actions are systemic appetite suppression and glycemic control. Semaglutide is FDA-approved (for diabetes and obesity); survodutide is not yet approved.
MASH represents a large unmet medical need — it affects millions globally and has historically lacked effective pharmacological treatments. The combination of GLP-1R appetite suppression reducing caloric-driven hepatic lipid influx and GCGR-mediated hepatic fat oxidation enhancing lipid disposal is theoretically well-matched to MASH pathophysiology, where hepatocyte lipid overload drives inflammation and fibrosis. Phase 2 data showing robust liver fat reduction and histological improvement validated the mechanistic hypothesis, justifying Phase 3 investment.
Glucagon stimulates hepatic glucose production and would raise blood sugar if given alone. In survodutide, the concurrent GLP-1 receptor activation drives glucose-dependent insulin secretion, which counterbalances the glucagon-mediated glucose rise. Phase 2 data confirmed that net glycemic effect was controlled in both diabetic and non-diabetic participants. The peptide’s design intentionally balances these opposing glycemic signals to maintain euglycemia while preserving the hepatic fat-oxidizing benefits of glucagon signaling.
Resmetirom is a thyroid hormone receptor-beta agonist — mechanistically entirely distinct from survodutide. Resmetirom received FDA approval in 2024 for MASH with moderate to advanced fibrosis, making it the first approved MASH-specific treatment. It is taken orally once daily. Survodutide, if approved, would be an injectable once-weekly competitor with a different mechanism that may suit different patient profiles. Head-to-head trials do not yet exist. The MASH field is likely to accommodate multiple approved agents targeting different mechanisms, similar to the evolution of the diabetes drug landscape.
Survodutide is available only through enrollment in sponsored clinical trials. It is not commercially available and cannot be obtained outside of formal clinical research programs. Patients or investigators interested in survodutide access should consult ClinicalTrials.gov for currently enrolling studies in the SYNCHRONY Phase 3 program or other Boehringer Ingelheim-sponsored survodutide trials. No legitimate source of pharmaceutical-grade survodutide outside of these authorized channels exists at this time.
MASH stands for metabolic dysfunction-associated steatohepatitis and is the newer preferred term for what was previously called non-alcoholic steatohepatitis (NASH). The terminology shift reflects a broader renaming of the disease category: NAFLD (non-alcoholic fatty liver disease) was renamed MASLD (metabolic dysfunction-associated steatotic liver disease) to better capture the metabolic drivers of the condition and remove the historically stigmatizing “non-alcoholic” framing. The “MASH” term emphasizes the metabolic etiology — obesity, insulin resistance, dyslipidemia — rather than defining the disease by the absence of alcohol use. Survodutide trials initiated before this nomenclature change may use the older NASH terminology in publications.
Phase 3 SYNCHRONY trials are ongoing as of 2026, and timelines for regulatory submission will depend on when the primary efficacy endpoints are reported and analyzed. Given typical Phase 3 trial durations of two to three years plus regulatory review time, a potential regulatory decision could be anticipated in the 2027–2029 timeframe if Phase 3 trials succeed, though this estimate is speculative and subject to enrollment pace, regulatory feedback, and data outcomes. The AI Coach can provide the most current development timeline information as it becomes available.
Yes — survodutide is the most advanced dual GLP-1R/GCGR agonist as of 2026, but it is not alone in this class. AstraZeneca and other companies have investigational dual and triple agonists in development targeting combinations of GLP-1R, GCGR, and GIP receptors. Tirzepatide, now approved as a GIP/GLP-1 dual agonist, does not include glucagon receptor agonism. The therapeutic rationale for GCGR co-activation specifically for hepatic steatosis is distinct from the GIP/GLP-1 dual agonism rationale, which is primarily focused on incretin synergy for weight and glucose outcomes. The Peptide Database contains comparison profiles for compounds across this mechanistic landscape.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.